Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5):603-615.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Wolchok, Jedd D; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C Lance; Lao, Christopher D; Wagstaff, John; Schadendorf, Dirk; Ferrucci, Pier F; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; Haanen, John; Carlino, Matteo S; et al (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14):1345-1356.

Coens, Corneel; Suciu, Stefan; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Celeste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bottomley, Andrew; Kotapati, Srividya; de Pril, Veerle; Testori, Alessandro; Eggermont, Alexander M M (2017). Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, 18(3):393-403.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen; Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2016). Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19):1845-1855.

Grob, Jean Jacques; Amonkar, Mayur M; Karaszewska, Boguslawa; Schachter, Jacob; Dummer, Reinhard; Mackiewicz, Andrzej; Stroyakovskiy, Daniil; Drucis, Kamil; Grange, Florent; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Lichinitser, Mikhail; Levchenko, Evgeny; Wolter, Pascal; Hauschild, Axel; Long, Georgina V; Nathan, Paul; Ribas, Antoni; Flaherty, Keith; Sun, Peng; Legos, Jeffrey J; McDowell, Diane Opatt; Mookerjee, Bijoyesh; Schadendorf, Dirk; Robert, Caroline (2015). Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncology, 16(13):1389-1398.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Konto, Cyril; Hoos, Axel; de Pril, Veerle; Gurunath, Ravichandra Karra; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncology, 16(5):522-530.

Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D; Little, Shonda M; Schadendorf, Dirk (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine, 372(1):30-39.

This list was generated on Mon Aug 20 14:44:05 2018 CEST.